Additionally, the 36-month beta value for APDN is 0.33. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for APDN is 10.29M and currently, short sellers hold a 16.95% ratio of that float. The average trading volume of APDN on October 22, 2024 was 10.33M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
APDN) stock’s latest price update
The stock of Applied Dna Sciences Inc (NASDAQ: APDN) has increased by 15.85 when compared to last closing price of 0.32. Despite this, the company has experienced a 25.00% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-10-15 that STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA”), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.
APDN’s Market Performance
Applied Dna Sciences Inc (APDN) has experienced a 25.00% rise in stock performance for the past week, with a -69.88% drop in the past month, and a -8.47% drop in the past quarter. The volatility ratio for the week is 16.53%, and the volatility levels for the past 30 days are at 16.52% for APDN. The simple moving average for the past 20 days is -22.27% for APDN’s stock, with a -92.02% simple moving average for the past 200 days.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -64.67% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.36% of loss for the given period.
Volatility was left at 16.52%, however, over the last 30 days, the volatility rate increased by 16.53%, as shares sank -66.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.17% upper at present.
During the last 5 trading sessions, APDN rose by +25.00%, which changed the moving average for the period of 200-days by -97.00% in comparison to the 20-day moving average, which settled at $0.4824. In addition, Applied Dna Sciences Inc saw -96.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -4.39 for the present operating margin
- 0.16 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -2.17. The total capital return value is set at -1.09. Equity return is now at value -74.21, with -44.88 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -15.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 7.43.
Currently, EBITDA for the company is -10.45 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of -1.68. The receivables turnover for the company is 6.61for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.91.
Conclusion
In conclusion, Applied Dna Sciences Inc (APDN) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
